Rhodes Pharmaceuticals L.P.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.3M
Doctors Paid
3,297
Transactions
9,061
2024 Total
$134,882
Payment Breakdown by Category
Research$3.9M (73.9%)
Consulting$1.1M (20.5%)
Food & Beverage$136,264 (2.6%)
Travel$42,767 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 379 | 73.9% |
| Consulting Fee | $1.1M | 73 | 20.5% |
| Food and Beverage | $136,264 | 8,406 | 2.6% |
| Honoraria | $117,533 | 57 | 2.2% |
| Travel and Lodging | $42,767 | 146 | 0.8% |
Payments by Type
Research
$3.9M
379 transactions
General
$1.4M
8,682 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| RP-BP-EF003 | $1.4M | 11 | 120 |
| A Multiple-Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Test Vehicle Patch (for Scopolamine Transdermal System) (Rhodes Pharmaceuticals L.P.) | $1.0M | 0 | 5 |
| RP-BP-EF004 | $686,767 | 12 | 186 |
| A Randomized, Open-Label, Two-Treatment, Two-Period, Four-Sequence Crossover Study to Evaluate the Relative Bioavailability and Adhesive Properties of a Test Scopolamine Transdermal System, 1 mg/3 days (Rhodes Pharmaceuticals L.P.) when compared to Transderm Sc?p? (scopolamine transdermal system), 1 mg/3 days (ALZA Corporation) in Healthy Adult Subjects | $509,214 | 0 | 5 |
| Scopolamine Efficacy | $142,500 | 1 | 1 |
| A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules Aptensio XR in Children Ages 4-5 Years Diagnosed with Attention-DeficitHyperactivity Disorder ADHD | $86,959 | 0 | 20 |
| RP-BP-PK003 | $44,147 | 1 | 8 |
| EF-003 | $16,704 | 1 | 4 |
| A Randomized, Open-Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Evaluate the Relative Bioavailability and Adhesive Properties of Two Test Scopolamine Transdermal System, 1 mg/3 days (Manufactured for Rhodes Pharmaceuticals L.P.) when compared to Transderm Scp (scopolamine) Transdermal System, 1.5 mg (Novartis Consumer Health, Inc.) in Healthy Adult Subjects. | $9,033 | 0 | 8 |
| Single dose oral bioequivalence study of Lisdexamfetamine dimesylate Capsule 70 mg (Rhodes Pharmaceuticals L.P.) and VYVANSE (lisdexamfetamine dimesylate) Capsules 70 mg (Shire US Inc.) in healthy adult human subjects under fed conditions. | $8,241 | 0 | 10 |
| Single dose oral bioequivalence study of Lisdexamfetamine dimesylate Capsule 70 mg (Rhodes Pharmaceuticals L.P.) and VYVANSE (lisdexamfetamine dimesylate) Capsules 70 mg (Shire US Inc.) in healthy adult human subjects under fasting conditions. | $6,592 | 0 | 8 |
| Lisdexamfetamine Capsule 70mg 2-way Crossover Fasting Pivotal | $2,606 | 0 | 2 |
| Clonidine Efficacy | $2,110 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Valerie Arnold, Md, MD | Child & Adolescent Psychiatry | Memphis, TN | $643,335 | $0 |
| Jorge Lujan-Zilbermann, M.d, M.D | Pediatrics | Tampa, FL | $361,396 | $0 |
| Dr. Nelson Handal, M.d, M.D | Child & Adolescent Psychiatry | Dothan, AL | $302,716 | $0 |
| J Sartore, Md, MD | Family Medicine | Evansville, IN | $281,105 | $0 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $161,305 | $0 |
| Dr. Michael Greenbaum, Md, MD | Psychiatry | Libertyville, IL | $154,588 | $0 |
| Thresa Simon, M.d, M.D | Psychiatry | Petersburg, VA | $145,595 | $0 |
| Dr. Robert Weaver, M.d, M.D | Medical Oncology | Houston, TX | $142,500 | $0 |
| Samantha Bostrom, Md, MD | Pediatrics | Clinton, UT | $140,441 | $0 |
| Jose Zaglul, Md, MD | Child & Adolescent Psychiatry | Bradenton, FL | $129,511 | $0 |
| Mr. Americo Padilla, Md, MD | Psychiatry | Miami, FL | $96,091 | $0 |
| Eric Cure, Md, MD | Emergency Medicine | Evansville, IN | $62,131 | $0 |
| Dr. Corey Hebert | Pediatrics | Gretna, LA | $50,616 | $0 |
| Dr. Arifulla Khan, Md, MD | Psychiatry | Bellevue, WA | $43,910 | $0 |
| Dr. Birgit Amann, M.d, M.D | Child & Adolescent Psychiatry | Troy, MI | $34,693 | $0 |
| Dr. Frank Lopez, Md, MD | Neurodevelopmental Disabilities | Winter Park, FL | $18,994 | $0 |
| Dr. Joel Young, Md, MD | Psychiatry | Rochester Hills, MI | $17,579 | $0 |
| Dr. Michael Feld, M.d, M.D | Psychiatry | Northbrook, IL | $16,898 | $0 |
| David Brougher, M.d, M.D | Family Medicine | Evansville, IN | $9,227 | $0 |
| Dr. Marcus Degraw, Md, MD | Pediatrics | Detroit, MI | $6,300 | $0 |
| Dr. Morris Levinsohn, M.d, M.D | Neurology | Willoughby, OH | $5,485 | $0 |
| Dr. Daniel Tan, M.d, M.D | Psychiatry | Houston, TX | $5,188 | $0 |
| Dr. Alice Mao, Md, MD | Child & Adolescent Psychiatry | Houston, TX | $3,327 | $0 |
| Unknown Provider | — | — | $3,311 | $0 |
| Jeffrey Newcorn, M.d, M.D | Child & Adolescent Psychiatry | New York, NY | $2,700 | $0 |
Ad
Top Products
- Aptensio XR $2.6M
Associated Products (1)
- Aptensio XR $2.6M
Payment Categories
- Food & Beverage $136,264
- Consulting $1.1M
- Travel & Lodging $42,767
- Research $3.9M
About Rhodes Pharmaceuticals L.P.
Rhodes Pharmaceuticals L.P. has made $5.3M in payments to 3,297 healthcare providers, recorded across 9,061 transactions in the CMS Open Payments database. In 2024, the company paid $134,882. The top product by payment volume is Aptensio XR ($2.6M).
Payments were distributed across 72 medical specialties. The top specialty by payment amount is Child & Adolescent Psychiatry ($1.3M to 212 doctors).
Payment categories include: Food & Beverage ($136,264), Consulting ($1.1M), Research ($3.9M), Travel & Lodging ($42,767).
Rhodes Pharmaceuticals L.P. is associated with 1 products in the CMS Open Payments database.